Literature DB >> 2113220

The effect of fish-oil dietary supplement on the progression of mesangial IgA glomerulonephritis.

I K Cheng1, P C Chan, M K Chan.   

Abstract

The effect of fish-oil dietary supplement on the rate of progression of renal failure in 11 patients with IgA nephropathy was investigated by comparing the slope of the plot of reciprocal serum creatinine versus time before and after supplement. After supplement, the slope significantly decreased in two patients, increased in two, and was not significantly altered in the remainder. Before supplement, serum IgA, IgA circulating immune complexes, and in-vitro Ig production were not significantly different from normal controls. After supplement, urinary protein transiently increased, serum IgA circulating immune complexes decreased, and serum triglyceride and in-vitro platelet aggregation tended to decrease. Only the change in serum IgG and spontaneous in-vitro IgG production correlated with the change in the rate of renal functional deterioration. No clinical or biochemical parameters before supplement predicted the subsequent response. In patients with IgA nephropathy, non-immune factors probably contribute to progression of renal failure, and in these patients fish-oil dietary supplement has either no demonstrable or an unpredictable effect.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2113220     DOI: 10.1093/ndt/5.4.241

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  7 in total

Review 1.  Recognition and management of IgA nephropathy.

Authors:  L S Ibels; A Z Gyory; R J Caterson; C A Pollock; J F Mahony; D A Waugh; S Coulshed
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

Review 2.  Treatment of IgA nephropathy.

Authors:  C Y Lin
Journal:  Springer Semin Immunopathol       Date:  1994

3.  Serum oxylipin profiles in IgA nephropathy patients reflect kidney functional alterations.

Authors:  Angela M Zivkovic; Jun Yang; Katrin Georgi; Christine Hegedus; Malin L Nording; Aifric O'Sullivan; J Bruce German; Ronald J Hogg; Robert H Weiss; Curt Bay; Bruce D Hammock
Journal:  Metabolomics       Date:  2012-12       Impact factor: 4.290

Review 4.  Omega 3 fatty acids for prevention and treatment of cardiovascular disease.

Authors:  L Hooper; R L Thompson; R A Harrison; C D Summerbell; H Moore; H V Worthington; P N Durrington; A R Ness; N E Capps; G Davey Smith; R A Riemersma; S B J Ebrahim
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

5.  Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.

Authors:  Asmaa S Abdelhamid; Tracey J Brown; Julii S Brainard; Priti Biswas; Gabrielle C Thorpe; Helen J Moore; Katherine Ho Deane; Fai K AlAbdulghafoor; Carolyn D Summerbell; Helen V Worthington; Fujian Song; Lee Hooper
Journal:  Cochrane Database Syst Rev       Date:  2018-11-30

Review 6.  Omega-3 fatty acid supplementation as an adjunctive therapy in the treatment of chronic kidney disease: a meta-analysis.

Authors:  Jing Hu; Zuoliang Liu; Hao Zhang
Journal:  Clinics (Sao Paulo)       Date:  2017-01-01       Impact factor: 2.365

Review 7.  Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.

Authors:  Asmaa S Abdelhamid; Tracey J Brown; Julii S Brainard; Priti Biswas; Gabrielle C Thorpe; Helen J Moore; Katherine Ho Deane; Fai K AlAbdulghafoor; Carolyn D Summerbell; Helen V Worthington; Fujian Song; Lee Hooper
Journal:  Cochrane Database Syst Rev       Date:  2018-07-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.